stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) EPS (diluted)
Liquidia Corporation's EPS (diluted) for fiscal 2025 was −$0.80, compared with −$1.66 in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.37. Over the past ten years it has ranged from −$51.77 (fiscal 2017) to −$0.67 (fiscal 2022); the current reading is higher than 82% of that period. Liquidia Corporation ranks 11th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.80 | — |
| FY2024 | −$1.66 | — |
| FY2023 | −$1.21 | — |
| FY2022 | −$0.67 | — |
| FY2021 | −$0.70 | — |
| FY2020 | −$1.76 | — |
| FY2019 | −$2.59 | — |
| FY2018 | −$7.51 | — |
| FY2017 | −$51.77 | — |
| FY2017 | −$1.85 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.74 | 42.31% |
| Mar 2026 | $0.52 | 246.67% |
| Dec 2025 | $0.15 | — |
| Sep 2025 | −$0.04 | — |
| 32 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| SUPN Indivior Pharmaceuticals Inc. compare | $3.58 |
| PBH Prestige Consumer Healthcare Inc. compare | $3.24 |
| LQDA Liquidia Corporation | $1.37 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$1.43 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LQDA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement